



Curriculum Vitae

Personal information **Enrico Costa**

Work experience

1. Employer: Italian Medicines Agency
 - Start date: 102020
 - End date:
 - Position: Head of International Affairs Department
 - Activities: Coordination of AIFA's international activities
 - Country: Italy
2. Employer: University Hospital of Verona _ Department of Pharmacy
 - Start date: 122010
 - End date: 092020
 - Position: Pharmacist Health Official _ Hospital Pharmacy
 - Activities: Person in charge of the clinical governance of medicines Elaboration and drafting of evidence_based steering documents
 - Country: Italy
3. Employer: University Hospital of Verona _ Department of Pharmacy
 - Start date: 032004
 - End date: 122010
 - Position: Clinical Pharmacist (Contract staff)
 - Activities: Pharmacoepidemiology, analysis and monitoring of medicines use, scientific information, drug compounding and dispensing
 - Country: Italy
4. European Medicines Agency
 - Start date: 062021
 - End date:
 - Position: Member of the Committee for Orphan Medicinal Products (COMP)
 - Activities:
 - Country: Netherlands

Education and training

1. Subject: Utrecht University
 - Start date: 012019
 - End date:
 - Qualification: Professional PhD Fellow at the WHO Collaborating Centre for Pharmaceutical Policy and Regulation
 - Organisation:
 - Country: Netherlands
2. Subject: University of Milan
 - Start date: 122003
 - End date: 072006
 - Qualification: Post_graduate specialisation in Hospital Pharmacy
 - Organisation:
 - Country: Italy
3. Subject: Italian Cochrane Centre _ Istituto di Ricerche Farmacologiche Mario Negri _ Milan
 - Start date: 052005
 - End date: 062006
 - Qualification: Post_graduate Visiting fellow
 - Organisation:
 - Country: Italy
4. Subject: Industrial Toxicology Lab – University of Parma
 - Start date: 032003
 - End date: 122003
 - Qualification: Post_graduate Visiting fellow
 - Organisation:
 - Country: Italy
5. Subject: University of Bologna
 - Start date: 111995
 - End date: 062002
 - Qualification: Degree in Pharmacy
 - Organisation:
 - Country: Italy
6. Subject: University of Bologna
 - Start date: 062001
 - End date: 062002
 - Qualification: Visiting student _ Applied Pharmacology Lab
 - Organisation:
 - Country: Italy
7. Subject: Centre of Xenobiotics Research, Ninewells Hospital and Medical School _ University of Dundee
 - Start date: 072000
 - End date: 082000
 - Qualification: Visiting student

- Organisation:
- Country: United Kingdom

Additional information

Publications

Last publications 1. Costa E, Tanno LK, Salazzari D, Tedeschi F, Andretta M, Caminati M. Trends and determinants of epinephrine prescriptions: a proxy of anaphylaxis epidemiology? *Curr Opin Allergy Clin Immunol*. 2022 Dec 1;22(6):441_449. 2. Costa E, Girotti S, Pauro F, Leufkens HGM, Cipolli M. The impact of FDA and EMA regulatory decision making process on the access to CFTR modulators for the treatment of cystic fibrosis. *Orphanet J Rare Dis*. 2022 May 7;17(1):188. 3. Costa E, Cappellini MD, Rivella S, Chilin A, Alessi E, Riccaboni M, Leufkens HGM, Luzzatto L. Emergent treatments for β -thalassaemia and orphan drug legislations. *Drug Discov Today*. 2022 Sep 1;27(11):103342. 4. De Franceschi L, Costa E, Dima F, Morandi M, Olivieri O. Glucose 6-phosphate dehydrogenase deficiency associated hemolysis in COVID-19 patients treated with hydroxychloroquine/chloroquine: New case reports coming out. *Eur J Intern Med*. 2020 Oct; 80:103. doi: 10.1016/j.ejim.2020.08.015. Epub 2020 Aug 13. [PMID: 32819797] 5. Costa E, Sterzi E, Tedeschi F, Casari R, Marini P, Lugoboni F. Can oral formulation increase the risk of lorazepam abuse? *Intern Emerg Med*. 2020 Oct 23. doi: 10.1007/s11739_020_02538_2. [PMID: 33095413]. 6. Costa E, Tibalinda P, Sterzi E, Leufkens HGM, Makani J, Kaale E, Luzzatto L. Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost. *Am J Hematol*. 2021 Jan;96(1): E2_E5. doi: 10.1002/ajh.26007. Epub 2020 Oct 6. [PMID: 32974896] 7. De Franceschi L, Costa E, Dima F, Morandi M, Olivieri O. Acute hemolysis by hydroxychloroquine was observed in G6PD-deficient patient with severe COVID-19 related lung injury. *Eur J Intern Med*. 2020 Jul; 77:136_137. doi: 10.1016/j.ejim.2020.04.020. Epub 2020 Apr 20. [PMID: 32381323]; 8. Costa E, Schieppati A, Luzzatto L, Remuzzi G. Drugs for rare diseases: the blessing of being orphans. *Recent Prog Med*. 2019 May;110(5):221_229. doi: 10.1701/3163.31444. [PMID: 31140454] 9. Luzzatto L, Costa E, Schieppati A, Remuzzi G. Orphan drugs _ Authors' reply. *Lancet*. 2019 Apr 20; 393(10181):1595_1596. doi: 10.1016/S0140_6736(19)30014_5. [PMID: 31007199] 10. Luzzatto L, Hyry HI, Schieppati A, Costa E, Simoens S, Schaefer F, Roos JCP, Merlini G, Kääräinen H, Garattini S, Hollak CE, Remuzzi G. Outrageous prices of orphan drugs: a call for collaboration. *Lancet*. 2018 Sep 1;392(10149):791_794. doi: 10.1016/S0140_6736(18)31069_9. Epub 2018 Jul 20. [PMID: 30037734]

Projects

Memberships

Other Relevant Information